Loading
Top

News

Scroll Down

Taking a novel approach to drug development

News

Lantern Pharma is proud to be featured in multitude of media outlets. Our goal is to crush cancer by leveraging A.I. and machine learning. By sharing our message and news, we hope to foster additional collaborations and partnerships, and engage with the clinical community in developing the right treatments for the right patients.

January 25, 2024

The trends that will shape the biotech industry in 2024

Read Now
Read Now
Download Now
January 23, 2024

Navigating the Crossroads of AI and Oncology: A Deep Dive with Lantern Pharma's CEO, Panna Sharma

Read Now
Read Now
Download Now
December 5, 2023

FDA Grants Orphan Drug Designation to LP-284 for Treatment of HGBL With MYC, BCL2 Rearrangements

Read Now
Read Now
Download Now
December 4, 2023

FDA Grants Orphan Drug Designation to LP-284 for High-Grade B-Cell Lymphomas

Read Now
Read Now
Download Now
November 6, 2023

How Lantern Pharma and Code Ocean partnered on oncology drug development

Read Now
Read Now
Download Now
November 2, 2023

Building a Path to Cure for Patients With NSCLC Who Have Never Smoked

Read Now
Read Now
Download Now
September 26, 2023

Lantern Pharma doses first patient in solid tumour drug trial

Read Now
Read Now
Download Now
July 21, 2023

9 Notable AI Companies in Clinical Research to Watch in 2023

Read Now
Read Now
Download Now
July 13, 2023

AI Breaches the Barrier Towards Better CNS Drug Discovery

Read Now
Read Now
Download Now
June 14, 2023

Dallas firm’s experimental cancer drug set to begin human trials this summer

Read Now
Read Now
Download Now
June 13, 2023

Unveiling Lantern Pharma's Success Story in AI-powered Precision Oncology

Read Now
Read Now
Download Now
June 13, 2023

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

Read Now
Read Now
Download Now
June 13, 2023

Using AI in the Development of Novel ADCs: Lantern Pharma and Bielefeld University to Cooperate

Read Now
Read Now
Download Now
June 12, 2023

Lantern Pharma to Study LP-184 in DNA Damage Response-Deficient Solid Tumors

Read Now
Read Now
Download Now
June 12, 2023

Lantern Pharma Offers AI Platform for ADC Discovery with Bielefeld University

Read Now
Read Now
Download Now
May 11, 2023

Lantern Pharma launches a cutting-edge AI algorithm

Read Now
Read Now
Download Now
May 2, 2023

Busting the Brain’s Firewall: How Lantern Pharma’s Algorithms Can Predict a Drug’s Ability to Reach the Brain

Read Now
Read Now
Download Now
January 17, 2023

Lantern Pharma Preparing IND for Synthetic Lethality Program With FDA Feedback

Read Now
Read Now
Download Now
January 9, 2023

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

Read Now
Read Now
Download Now
December 26, 2022

LP-284 Exhibits Preclinical Efficacy in DDR-Deficient MCL

Read Now
Read Now
Download Now
December 22, 2022

Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise

Read Now
Read Now
Download Now
November 21, 2022

BPT20: Artificial Intelligence in Drug Discovery Productivity Index

Read Now
Read Now
Download Now
November 20, 2022

Powering Cancer Drug Discovery and Development Using the Artificial Intelligence and Machine Learning Platform RADR®

Read Now
Read Now
Download Now
November 18, 2022

LP-284 Shows Preclinical Activity in ATM-Mutated MCL

Read Now
Read Now
Download Now
October 6, 2022

Lantern Pharma releases positive Preclinical Data on Efficacy of LP-284 for Mantle Cell Lymphoma

Read Now
Read Now
Download Now
September 26, 2022

Highs and lows of drug repurposing

Read Now
Read Now
Download Now
September 15, 2022

Study Finds New Synthetic Lethal Agent Could Be Potential Treatment for Pancreatic Cancer

Read Now
Read Now
Download Now
September 14, 2022

Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate

Read Now
Read Now
Download Now
July 19, 2022

Lantern Pharma's New Phase 2 Clinical Trial –Harmonic™ — Approved for Launch by the FDA

Read Now
Read Now
Download Now
July 14, 2022

Lantern Pharma Gets FDA Nod to Begin Phase II Trial of LP-300 in Biomarker-Defined NSCLC

Read Now
Read Now
Download Now
April 14, 2022

Lantern Pharma: transforming oncology drug development with AI

Read Now
Read Now
Download Now
February 24, 2022

Nearly 300 Novel Agents Currently in Development for Rare Cancers

Read Now
Read Now
Download Now
February 2, 2022

This Pharma Company Is Using Machine Learning And AI To Attempt To Transform Oncology Drug Development Processes

Read Now
Read Now
Download Now
January 28, 2022

Lantern Pharma is Using Artificial Intelligence to Develop Oncology Treatments

Read Now
Read Now
Download Now
January 27, 2022

Episode 703: Panna Sharma on Leveraging Artificial Intelligence To Rescue and Develop Cancer Therapies

Action & Ambition Podcast

Read Now
Read Now
Download Now
January 24, 2022

Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT)

Read Now
Read Now
Download Now
January 18, 2022

Lantern Pharma Collaborating With Danish Cancer Research Center on Drugs for NER-Deficient Tumors

Read Now
Read Now
Download Now
January 13, 2022

Lantern Pharma and NCI expand oncology partnership

Read Now
Read Now
Download Now
January 12, 2022

Lantern Pharma rises 9% on team up with National Cancer Institute for drug candidates

Read Now
Read Now
Download Now
December 14, 2021

Lantern Pharma (LTRN) Reports Positive Efficacy Data of LP-284 in Hematologic Cancers

Read Now
Read Now
Download Now
December 6, 2021

What is the Real Cost of Developing Medicine?

Healthcare Americana Podcast

Read Now
Read Now
Download Now
November 17, 2021

Cost of Care: Defanged drug pricing reform means less of a bite for Big Pharma

Read Now
Read Now
Download Now
November 8, 2021

The Local Oncology Innovator ‘Smashing’ Drug Development Timelines

Read Now
Read Now
Download Now
November 2, 2021

Why we are on the cusp of a golden age of medicine

Read Now
Read Now
Download Now
October 20, 2021

The AI Pharmacist: How Artificial Intelligence Can Accelerate Drug Development

Read Now
Read Now
Download Now
September 24, 2021

Slice of Healthcare Podcast #192 – Panna Sharma, CEO & President at Lantern Pharma

Read Now
Read Now
Download Now
September 22, 2021

How Technologies Like AI and Machine Learning Can Help With the Development of Medicine

TradeTalks Video Broadcasts - With Jill Malandrino

Read Now
Read Now
Download Now
September 12, 2021

BioBoss Podcast #39 - Panna Sharma, CEO of Lantern Pharma

Read Now
Read Now
Download Now
September 2, 2021

Biotech is sprouting into Dallas-Fort Worth’s next big thing, based on seeds planted decades ago

Read Now
Read Now
Download Now
August 26, 2021

Join our team and help transform the cancer drug development process, cost and timeline!

Read Now
Read Now
Download Now
August 16, 2021

Behind the Study: Retaining Nanomolar Potency in Lung Cancer

Read Now
Read Now
Download Now
August 3, 2021

Lantern Pharma CEO Shares His Four Secrets to Turning a Startup into an IPO

Read Now
Read Now
Download Now
July 30, 2021

Benzinga's Power Hour Show

Read Now
Read Now
Download Now
July 28, 2021

How AI Is Expediting Medicine Development

Read Now
Read Now
Download Now
July 26, 2021

Allarity Therapeutics, Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

Read Now
Read Now
Download Now
July 22, 2021

Dallas region sees growing traction around the life sciences amid IPOs, fundings

Read Now
Read Now
Download Now
July 20, 2021

Preclinical Data on New Pancreatic Cancer Drug Shines with over 90% Efficacy

Read Now
Read Now
Download Now
July 20, 2021

Midday Hot Stocks: SPCE falls as Bezos flies; HAL, UBS rise on earnings; LTRN gets strong pre-clinical data

Read Now
Read Now
Download Now
July 9, 2021

How AI Is Transforming the Healthcare Landscape & Accelerating the Development of Medicine

Read Now
Read Now
Download Now
May 3, 2021

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence Platform

Read Now
Read Now
Download Now
April 29, 2021

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company’s Progress in the Development of Biopharma Collaborations and Partnerships and Advancing

Read Now
Read Now
Download Now
April 13, 2021

New Lantern Manuscript: The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations

Read Now
Read Now
Download Now
March 17, 2021

Lantern ($LTRN) Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with

Read Now
Read Now
Download Now
March 4, 2021

A machine learning‐based gene signature of response to the novel alkylating agent LP‐184 distinguishes its potential tumor indications

Read Now
Read Now
Download Now
January 23, 2021

Technology Is Rapidly Changing Cancer Care

Read Now
Read Now
Download Now
December 10, 2020

AI offers promise but faces barriers in drug development

Read Now
Read Now
Download Now
November 18, 2020

Dallas’ Lantern Pharma Hits Major Milestone on its AI Platform to Advance its Oncology Drug Research and Development

Read Now
Read Now
Download Now
October 29, 2020

Episode 68: Rocking Garage Biotech

Read Now
Read Now
Download Now
September 29, 2020

What going public means for Lantern Pharma

Read Now
Read Now
Download Now
September 23, 2020

Lantern Pharma, Fox Chase Partner on Pancreatic Cancer Drug, Search for Predictive Gene Signature

Read Now
Read Now
Download Now